Beyond Air Reports 107% FY26 Revenue Growth, Projects >110% CY27 Growth Amidst Nasdaq Compliance Efforts
XAIR sits 44% above its 52-week low of $0.335 on elevated volume (3.6× avg).
Summary
Beyond Air reported strong fiscal year 2026 revenue growth and issued optimistic guidance for 2027, projecting over 110% growth, which is critical as the company faces a Nasdaq delisting deadline and a going concern warning.
Key Events · Earnings and Guidance · XAIR
-
Strong Fiscal Year 2026 Revenue Growth
Beyond Air reported a 107% year-over-year increase in revenue to $7.7 million for the fiscal year ended March 31, 2026, with Q4 revenue up 66% to $1.9 million.
-
Optimistic Revenue Guidance for 2026 and 2027
The company projects $8 million in revenue for calendar year 2026 (15% growth) and $16-$18 million for calendar year 2027, representing over 110% year-over-year growth at the midpoint.
-
Potential Market Expansion with Second-Generation Product
Awaiting FDA approval for its second-generation LungFit PH system, which, if approved with a broader label, could increase the total addressable U.S. market by 4x to approximately $400 million and worldwide to over $1 billion.
-
Fiscal Year-End Change Approved
The Board of Directors approved changing the company's fiscal year-end from March 31 to December 31, effective December 31, 2026, with a nine-month transition period.
Analysis · XAIR · Industrial Applications And Services
Beyond Air reported strong fiscal year 2026 revenue growth of 107% to $7.7 million, with Q4 revenue up 66%. More significantly, the company provided revenue guidance of $8 million for calendar year 2026 (15% growth) and $16-$18 million for calendar year 2027, representing over 110% year-over-year growth. This optimistic outlook is contingent on the FDA approval of its second-generation LungFit PH system, which could expand the total addressable U.S. market by 4x to $400 million and worldwide to over $1 billion. This positive forward-looking guidance is crucial for the company, which recently received a Nasdaq delisting notice and a going concern warning in its 10-K filed on the same day. The Board also approved a change in the fiscal year-end from March 31 to December 31, effective December 31, 2026, to align with calendar year reporting.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XAIR was trading at $0.48 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $6.3M. The 52-week trading range was $0.33 to $4.78. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.